Does the media favor MLAB or FTRE?

In the previous week, Mesa Laboratories had 2 more articles in the media than Fortrea. MarketBeat recorded 13 mentions for Mesa Laboratories and 11 mentions for Fortrea. Fortrea's average media sentiment score of 0.96 beat Mesa Laboratories' score of 0.68 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLFS or MLAB?

In the previous week, Mesa Laboratories had 9 more articles in the media than BioLife Solutions. MarketBeat recorded 13 mentions for Mesa Laboratories and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Mesa Laboratories' score of 0.68 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesa Laboratories 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AZTA or MLAB?

In the previous week, Mesa Laboratories had 11 more articles in the media than Azenta. MarketBeat recorded 13 mentions for Mesa Laboratories and 2 mentions for Azenta. Azenta's average media sentiment score of 1.43 beat Mesa Laboratories' score of 0.68 indicating that Azenta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesa Laboratories 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRVI or MLAB?

In the previous week, Mesa Laboratories had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 13 mentions for Mesa Laboratories and 5 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.88 beat Mesa Laboratories' score of 0.68 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Mesa Laboratories 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PSNL or MLAB?

In the previous week, Mesa Laboratories had 8 more articles in the media than Personalis. MarketBeat recorded 13 mentions for Mesa Laboratories and 5 mentions for Personalis. Personalis' average media sentiment score of 0.89 beat Mesa Laboratories' score of 0.68 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesa Laboratories 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mesa Laboratories (MLAB) Competitors

$108.64 -4.56 (-4.03%)

As of 01:00 PM Eastern

Compare

MLAB vs. FTRE, BLFS, AZTA, MRVI, and PSNL

Should you buy Mesa Laboratories stock or one of its competitors? Mesa Laboratories's main competitors and comparable companies include Fortrea (FTRE), BioLife Solutions (BLFS), Azenta (AZTA), Maravai LifeSciences (MRVI), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Mesa Laboratories compare to Fortrea?

Mesa Laboratories (NASDAQ:MLAB) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Mesa Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

Mesa Laboratories has a net margin of 1.92% compared to Fortrea's net margin of -3.18%. Mesa Laboratories' return on equity of 22.87% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.87%	9.75%
Fortrea	-3.18%	10.72%	2.17%

Mesa Laboratories has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.73M	2.45	$6.71M	$0.84	130.08
Fortrea	$2.72B	0.61	-$986.20M	-$0.91	N/A

90.6% of Mesa Laboratories shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mesa Laboratories had 2 more articles in the media than Fortrea. MarketBeat recorded 13 mentions for Mesa Laboratories and 11 mentions for Fortrea. Fortrea's average media sentiment score of 0.96 beat Mesa Laboratories' score of 0.68 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories currently has a consensus price target of $110.00, suggesting a potential upside of 0.67%. Fortrea has a consensus price target of $20.75, suggesting a potential upside of 18.71%. Given Fortrea's stronger consensus rating and higher probable upside, analysts plainly believe Fortrea is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Mesa Laboratories beats Fortrea on 10 of the 16 factors compared between the two stocks.

How does Mesa Laboratories compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

BioLife Solutions currently has a consensus target price of $31.38, indicating a potential downside of 10.42%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential upside of 0.67%. Given Mesa Laboratories' higher probable upside, analysts clearly believe Mesa Laboratories is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioLife Solutions has a net margin of 53.29% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.87% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Mesa Laboratories	1.92%	22.87%	9.75%

Mesa Laboratories has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	17.79	-$4.59M	$1.16	30.19
Mesa Laboratories	$249.73M	2.45	$6.71M	$0.84	130.08

BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

In the previous week, Mesa Laboratories had 9 more articles in the media than BioLife Solutions. MarketBeat recorded 13 mentions for Mesa Laboratories and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.77 beat Mesa Laboratories' score of 0.68 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 2.8% of Mesa Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioLife Solutions beats Mesa Laboratories on 9 of the 17 factors compared between the two stocks.

How does Mesa Laboratories compare to Azenta?

Azenta (NASDAQ:AZTA) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Mesa Laboratories has a net margin of 1.92% compared to Azenta's net margin of -20.63%. Mesa Laboratories' return on equity of 22.87% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Mesa Laboratories	1.92%	22.87%	9.75%

In the previous week, Mesa Laboratories had 11 more articles in the media than Azenta. MarketBeat recorded 13 mentions for Mesa Laboratories and 2 mentions for Azenta. Azenta's average media sentiment score of 1.43 beat Mesa Laboratories' score of 0.68 indicating that Azenta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Azenta presently has a consensus price target of $41.20, indicating a potential upside of 24.10%. Mesa Laboratories has a consensus price target of $110.00, indicating a potential upside of 0.67%. Given Azenta's stronger consensus rating and higher probable upside, research analysts clearly believe Azenta is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mesa Laboratories has lower revenue, but higher earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.45	-$55.76M	-$2.76	N/A
Mesa Laboratories	$249.73M	2.45	$6.71M	$0.84	130.08

Azenta has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

99.1% of Azenta shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Azenta beats Mesa Laboratories on 9 of the 16 factors compared between the two stocks.

How does Mesa Laboratories compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Maravai LifeSciences currently has a consensus target price of $6.25, suggesting a potential upside of 10.91%. Mesa Laboratories has a consensus target price of $110.00, suggesting a potential upside of 0.67%. Given Maravai LifeSciences' higher probable upside, equities analysts clearly believe Maravai LifeSciences is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maravai LifeSciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Mesa Laboratories has a net margin of 1.92% compared to Maravai LifeSciences' net margin of -37.07%. Mesa Laboratories' return on equity of 22.87% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.34%	-7.72%
Mesa Laboratories	1.92%	22.87%	9.75%

In the previous week, Mesa Laboratories had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 13 mentions for Mesa Laboratories and 5 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.88 beat Mesa Laboratories' score of 0.68 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	7.83	-$130.77M	-$0.52	N/A
Mesa Laboratories	$249.73M	2.45	$6.71M	$0.84	130.08

Summary

Mesa Laboratories beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Mesa Laboratories compare to Personalis?

Personalis (NASDAQ:PSNL) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Mesa Laboratories has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	21.32	-$81.27M	-$1.09	N/A
Mesa Laboratories	$249.73M	2.45	$6.71M	$0.84	130.08

Personalis has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

61.9% of Personalis shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Mesa Laboratories had 8 more articles in the media than Personalis. MarketBeat recorded 13 mentions for Mesa Laboratories and 5 mentions for Personalis. Personalis' average media sentiment score of 0.89 beat Mesa Laboratories' score of 0.68 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesa Laboratories	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories has a net margin of 1.92% compared to Personalis' net margin of -153.84%. Mesa Laboratories' return on equity of 22.87% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Mesa Laboratories	1.92%	22.87%	9.75%

Personalis currently has a consensus target price of $14.25, suggesting a potential upside of 0.48%. Mesa Laboratories has a consensus target price of $110.00, suggesting a potential upside of 0.67%. Given Mesa Laboratories' higher probable upside, analysts clearly believe Mesa Laboratories is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Mesa Laboratories beats Personalis on 10 of the 16 factors compared between the two stocks.

Get Mesa Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLAB vs. The Competition

Export

Metric	Mesa Laboratories	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$611.48M	$9.47B	$6.98B	$13.03B
Dividend Yield	0.58%	1.46%	2.58%	10.72%
P/E Ratio	130.08	60.42	269.56	25.24
Price / Sales	2.45	105.56	596.34	100.74
Price / Cash	9.58	26.03	70.53	50.75
Price / Book	3.24	38.04	13.02	6.32
Net Income	$6.71M	$56.66B	$3.45B	$347.92M
7 Day Performance	6.45%	0.21%	0.69%	0.91%
1 Month Performance	15.46%	1.47%	1.32%	0.89%
1 Year Performance	60.95%	19.23%	66.86%	20.28%

Mesa Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLAB Mesa Laboratories	1.2031 of 5 stars	$108.64 -4.0%	$110.00 +1.2%	+63.4%	$607.19M	$249.73M	129.17	680	News Coverage Earnings Report Analyst Upgrade
FTRE Fortrea	3.9193 of 5 stars	$19.52 +2.8%	$20.75 +6.3%	+127.3%	$1.86B	$2.72B	N/A	14,300
BLFS BioLife Solutions	3.0806 of 5 stars	$34.82 +0.5%	$31.38 -9.9%	+37.2%	$1.70B	$96.21M	30.02	440	Short Interest Increase
AZTA Azenta	3.4334 of 5 stars	$33.39 +0.2%	$41.20 +23.4%	+5.7%	$1.54B	$593.82M	N/A	3,000	Positive News Analyst Downgrade
MRVI Maravai LifeSciences	3.0718 of 5 stars	$5.81 -4.3%	$5.83 +0.4%	+110.2%	$1.50B	$185.74M	N/A	610

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLAB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesa Laboratories (MLAB) Competitors

MLAB vs. FTRE, BLFS, AZTA, MRVI, and PSNL

How does Mesa Laboratories compare to Fortrea?

Summary

How does Mesa Laboratories compare to BioLife Solutions?

Summary

How does Mesa Laboratories compare to Azenta?

Summary

How does Mesa Laboratories compare to Maravai LifeSciences?

Summary

How does Mesa Laboratories compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLAB vs. The Competition

Mesa Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesa Laboratories (MLAB) Competitors

MLAB vs. FTRE, BLFS, AZTA, MRVI, and PSNL

How does Mesa Laboratories compare to Fortrea?

Which has more risk & volatility, MLAB or FTRE?

Is MLAB or FTRE more profitable?

Which has preferable valuation & earnings, MLAB or FTRE?

Do institutionals & insiders hold more shares of MLAB or FTRE?

Does the media favor MLAB or FTRE?

Do analysts prefer MLAB or FTRE?

Summary

How does Mesa Laboratories compare to BioLife Solutions?

Do analysts prefer BLFS or MLAB?

Is BLFS or MLAB more profitable?

Which has higher valuation & earnings, BLFS or MLAB?

Which has more volatility & risk, BLFS or MLAB?

Does the media prefer BLFS or MLAB?

Do institutionals & insiders believe in BLFS or MLAB?

Summary

How does Mesa Laboratories compare to Azenta?

Is AZTA or MLAB more profitable?

Does the media refer more to AZTA or MLAB?

Do analysts rate AZTA or MLAB?

Which has better valuation & earnings, AZTA or MLAB?

Which has more risk and volatility, AZTA or MLAB?

Do insiders and institutionals believe in AZTA or MLAB?

Summary

How does Mesa Laboratories compare to Maravai LifeSciences?

Do analysts prefer MRVI or MLAB?

Do institutionals and insiders have more ownership in MRVI or MLAB?

Which has more volatility and risk, MRVI or MLAB?

Is MRVI or MLAB more profitable?

Does the media refer more to MRVI or MLAB?

Which has better earnings and valuation, MRVI or MLAB?

Summary

How does Mesa Laboratories compare to Personalis?

Which has better valuation and earnings, PSNL or MLAB?

Which has more risk and volatility, PSNL or MLAB?

Do institutionals and insiders hold more shares of PSNL or MLAB?

Does the media refer more to PSNL or MLAB?

Is PSNL or MLAB more profitable?

Do analysts prefer PSNL or MLAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLAB vs. The Competition

Mesa Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools